Mixed vaccination with ChAdOx1-S followed by BNT162b2 induces a robust humoral immune response
1. Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 ...
Tag: astrazeneca
Single dose mass vaccination against COVID-19 is linked with reductions in hospital admissions
1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one ...
#VisualAbstract: ChAdOx1 nCov-19 AstraZeneca COVID-19 vaccine not effective against B.1.351 variant
1. The ChAdOx1 nCov-19 (AstraZeneca) vaccine was not effective for the prevention of mild-to-moderate COVID-19 infection caused by the B.1.351 ...
ChAdOx1 nCov-19 AstraZeneca COVID-19 vaccine not effective against B.1.351 variant
1. The ChAdOx1 nCov-19 (AstraZeneca) vaccine was not effective for the prevention of mild-to-moderate COVID-19 infection caused by the B.1.351 ...
ChAdOx1 nCoV-19 (AstraZeneca) vaccine is effective against the SARS-CoV-2 B.1.1.7 variant
1. The AstraZeneca vaccine was 70.4% effective against the B.1.1.7 lineage, compared to 81.5% effective against non-B.1.1.7 lineages. 2. The ...
#VisualAbstract: ChAdOx1-nCoV-19 vaccine maintains efficacy despite a longer prime-boost interval
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, there ...
ChAdOx1-nCoV-19 vaccine maintains efficacy despite a longer prime-boost interval
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, ...
#VisualAbstract: Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise
Section 3: Oxford/AstraZeneca Vaccine Shows Promise for Phase 3 Outcomes With many COVID-19 vaccine being studied and approved for emergency ...
